Asset Details
Do you wish to reserve the book?
Three novel NY-ESO-1 epitopes bound to DRB10803, DQB10401 and DRB10901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Three novel NY-ESO-1 epitopes bound to DRB10803, DQB10401 and DRB10901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients
Do you wish to request the book?
Three novel NY-ESO-1 epitopes bound to DRB10803, DQB10401 and DRB10901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Three novel NY-ESO-1 epitopes bound to DRB10803, DQB10401 and DRB10901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients
2010
Overview
Three novel NY-ESO-1 CD4 T cell epitopes were identified using PBMC obtained from patients who were vaccinated with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein (CHP-NY-ESO-1). The restriction molecules were determined by antibody blocking and using various EBV-B cells with different HLA alleles as APC to present peptides to CD4 T cells. The minimal epitope peptides were determined using various N- and C-termini truncated peptides deduced from 18-mer overlapping peptides originally identified for recognition. Those epitopes were DRB1*0901-restricted NY-ESO-1 87–100, DQB1*0401-restricted NY-ESO-1 95–107 and DRB1*0803-restricted NY-ESO-1 124–134. CD4 T cells used to determine those epitope peptides recognized EBV-B cells or DC that were treated with recombinant NY-ESO-1 protein or NY-ESO-1-expressing tumor cell lysate, suggesting that the epitope peptides are naturally processed. These CD4 T cells showed a cytokine profile with Th1 characteristics. Furthermore, NY-ESO-1 87-100 peptide/HLA-DRB1*0901 tetramer staining was observed. Multiple Th1-type CD4 T cell responses are beneficial for inducing effective anti-tumor responses after NY-ESO-1 protein vaccination.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Cancer Vaccines - immunology
/ CD4-Positive T-Lymphocytes - immunology
/ CD4-Positive T-Lymphocytes - metabolism
/ Epitopes, T-Lymphocyte - immunology
/ Epitopes, T-Lymphocyte - metabolism
/ HLA-DR Antigens - immunology
/ HLA-DR Antigens - metabolism
/ Humans
/ Immunodominant Epitopes - immunology
/ Immunodominant Epitopes - metabolism
/ Neoplasm Proteins - immunology
/ Neoplasm Proteins - metabolism
/ NY-ESO-1
/ Peptides
/ Recombinant Proteins - immunology
/ Recombinant Proteins - metabolism
/ Vaccines
